TY - JOUR
T1 - Central nervous system relapse in a patient with mantle cell lymphoma in continuous clinical and molecular remission at six years since autografting
AU - Ladetto, M.
AU - Sametti, S.
AU - Astolfi, M.
AU - Corradini, P.
AU - Ricca, I.
AU - Drandi, D.
AU - Pileri, A.
AU - Tarella, C.
N1 - Funding Information:
This work was supported in part by Consiglio Nazi-onale delle Ricerche, Rome, Italy (special project A.C.R.O., grant # 96.00742.PF39 to C.T. and # 96.006 15.PF39 to A.P.) and by Associazione Italiana Ricerca sul Cancro, Milan, Italy.
PY - 2001
Y1 - 2001
N2 - Although molecular remissions have been frequently observed and associated with low likelihood of relapse in some lymphoid tumours, they are seldom reported in mantle cell lymphoma (MCL). We performed PCR analysis of a MCL patient with central nervous system (CNS) relapse occurring 76 months after autologous transplantation. Molecular follow-up showed constant absence of PCR-detectable disease, even after the onset of relapse. These data indicate that isolated CNS relapse may occur even after several years of continuous remission and cannot be excluded based on a persistent pattern of molecular remission. However, the prolonged remission duration observed in this patient suggests that achieving PCR-negativity may also be of benefit for MCL patients.
AB - Although molecular remissions have been frequently observed and associated with low likelihood of relapse in some lymphoid tumours, they are seldom reported in mantle cell lymphoma (MCL). We performed PCR analysis of a MCL patient with central nervous system (CNS) relapse occurring 76 months after autologous transplantation. Molecular follow-up showed constant absence of PCR-detectable disease, even after the onset of relapse. These data indicate that isolated CNS relapse may occur even after several years of continuous remission and cannot be excluded based on a persistent pattern of molecular remission. However, the prolonged remission duration observed in this patient suggests that achieving PCR-negativity may also be of benefit for MCL patients.
KW - Central nervous system relapse
KW - Immunoglobulin genes
KW - Mantle cell lymphoma
KW - Minimal residual disease
UR - http://www.scopus.com/inward/record.url?scp=0035048750&partnerID=8YFLogxK
U2 - 10.3109/10428190109097668
DO - 10.3109/10428190109097668
M3 - Article
SN - 1042-8194
VL - 40
SP - 679
EP - 682
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 5-6
ER -